Screener
Janux Therapeutics JANX Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Loss from operations | (31,690) | (45,118) | (65,903) | (80,015) |
| Other income: | ||||
| Interest income | 9,718 | 11,260 | 19,570 | 22,649 |
| Total other income | 9,718 | 11,260 | 19,570 | 22,649 |
| Net loss | $(21,972) | $(33,858) | $(46,333) | $(57,366) |
| Other comprehensive gain (loss): | ||||
| Unrealized gain (loss) on available-for-sale securities, net | (2,881) | (9) | (6,621) | 1,584 |
| Comprehensive loss | $(24,853) | $(33,867) | $(52,954) | $(55,782) |
Item 1. Financial Statements.
FAQ
- What is Janux Therapeutics's other income (expense)?
- Janux Therapeutics (JANX) reported other income (expense) of $9.72M in Q2 2026.
- How has Janux Therapeutics's other income (expense) changed year-over-year?
- Janux Therapeutics's other income (expense) decreased by 13.7% year-over-year, from $11.26M to $9.72M.
- What is the long-term trend for Janux Therapeutics's other income (expense)?
- Over 4 years (2021 to 2025), Janux Therapeutics's other income (expense) has grown at a 261.8% compound annual growth rate (CAGR), from $257K to $44.04M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Janux Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude